

CEMENT Q4FY25 Review 05 June 2025

## Listless YoY show; weak realisations offset by cost savings

 Volume growth at 9% YoY, driven by companies with healthy operating efficiencies. Southern companies under stress as prices stay weak Milind Raginwar research@bobcaps.in

- Cost saving offers respite EBITDA margins improve only to 20.3% vs 19.0% YoY; operating cost fell by ~2% YoY/QoQ
- Post results, we maintain our BUY ratings on UTCEM and STRCEM, and SELL on DALBHARA, JKLC and TRCL, Downgrade SRCM to SELL

**Healthy volume growth, realisations weaken by ~2% YoY:** Our coverage universe volumes grew at a healthy average ~9% YoY in Q4FY25, driven by well-managed companies. Weaker companies checked the volume to chase realisations impacting capacity utilisation. Demand recovery was healthy but a higher supply to meet the year-end targets, kept prices weak. UTCEM's volume grew ~10% YoY, despite its high base, while DALBHARA/TRCL's volumes fell by an average ~3.0%. Pricing pressure in high supply region (South) led to a ~2%/ YoY fall in realisations.

Cost-savings levers limited in future: Our cement universe EBITDA margins were listless YoY at 20.3% [on average], up 130bps YoY. STRCEM margins at 25%, JKCE and UTCEM at ~22.0%/21.8% beat the industry. ACC, JKLC and TRCL saw below-average margins of ~15%/14%/13% respectively. Aggregate EBITDA/t improved by ~2% YoY to Rs 926 vs Rs910 (Rs 651 Q3FY25).

Operating cost savings led by energy and logistic costs: Average fuel costs for our coverage universe fell by ~7%/4% YoY/QoQ, led by softer pet coke/coal prices. Logistics costs inched up by ~2% YoY as lead distance was higher to meet the yearend volume targets. Operating costs fell ~2% YoY/QoQ on an average to Rs 4,011/t.

**Demand slowed in Q4FY25:** Cement demand recovery was healthy YoY on a lower base, meeting year-end targets and relatively better infrastructure demand. However, heavy supply pressure in the eastern and southern India regions put pressure on prices. We stay optimistic about demand pickup in FY26, aided by the government's budget announcements, improving rural sentiment and affordability as well as steady real-estate demand. However, supply pressure will continue.

**UTCEM** is our top pick: We maintain UTCEM's BUY rating (TP Rs 13,919) as we believe it is best-placed to cater to the estimated demand growth with its higher capacity, better efficiencies and pan-India presence. We maintain SELL on TRCL (Rs 699), JKLC (Rs 728) and DALBHARA (Rs 1,742) due to their weak show. We retain HOLD on JKCE (Rs 5,208) and BUY on STRCEM (Rs 260), given its niche market presence. We downgrade SRCM (Rs 26,974) to SELL on steep valuations.





Fig 1 – Revenue growth

(Rs mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Comment
ACC	60,085	53,981	11.3	52,592	14.2	Aggregate revenue for our cement coverage
ACEM	56,814	47,803	18.8	48,537	17.1	recovered to ~7% despite southern companies
DALBHARA	40,910	43,073	(5.0)	31,810	28.6	falling in the 5-10% range.
JKCE	33,430	29,389	13.7	27,155	23.1	Volume gains were driven by efficient companies
JKLC	17,388	16,478	5.5	13,733	26.6	that could hit realisations (due to supply pressure)
SRCM	52,402	51,010	2.7	42,355	23.7	but could offset with cost savings. Weak operating
STRCEM	10,521	9,135	15.2	7,188	46.4	companies hit market share to arrest realisation
TRCL	23,920	26,733	(10.5)	19,766	21.0	fall. Realisations weakened by ~2% YoY as prices
UTCEM	2,11,347	1,98,059	6.7	1,63,284	29.4	remained weak in the southern and eastern regions of India in Q4.
Aggregate	5,06,815	4,75,662	6.5	4,06,419	24.7	

Source: Company, BOBCAPS Research

Fig 2 – EBITDA growth

(Rs mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Comment
ACC	8,806	8,371	5.2	4,725	86.3	Aggregate EBITDA for our coverage universe rose
ACEM	10,382	7,978	30.1	4,111	152.5	~13% YoY. The improvement would have been
DALBHARA	7,930	6,543	21.2	5,110	55.2	better, but for weakness by southern companies.  • UTCEM posted relatively healthy operating
JKCE	7,364	5,475	34.5	4,896	50.4	performance with 14% increase in EBITDA on a higher base.  JKLC performance was weak (down 12%) on higher cost structure, while TRCL fell 23% on
JKLC	2,424	2,755	(12.0)	1,425	70.1	
SRCM	13,867	13,272	4.5	9,466	46.5	
STRCEM	2,627	1,797	46.2	1,042	152.0	weak pricing and volume growth due to supply
TRCL	3,209	4,171	(23.1)	2,794	14.8	pressure in its key operating regions.
UTCEM	46,097	40,202	14.7	27,783	65.9	<ul> <li>SRCM gains were limited, despite lower capacity utilisation hovering ~ 65%.</li> </ul>
Aggregate	1,02,706	90,564	13.4	61,354	67.4	•

Source: Company, BOBCAPS Research

Fig 3 - Adj. PAT growth

(Rs mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Comment
ACC	6,808	4,913	38.6	(781)		- Aggregate DAT for our poverage universe gained
ACEM	9,289	5,481	69.5	2,266	310.0	<ul> <li>Aggregate PAT for our coverage universe gained by ~20% YoY higher than EBITDA on account of</li> </ul>
DALBHARA	4,350	3,153	38.0	610	613.1	weak base, improving balance sheets leading to
JKCE	3,629	2,265	60.3	2,048	77.2	lower interest outgo and tax benefits.
JKLC	1,380	1,424	(3.1)	595	131.9	lower interest outgo and tax perione.
SRCM	5,614	6,618	(15.2)	2,294	144.7	TRCL posted weakest profits due to higher
STRCEM	1,231	877	40.4	91	1259.8	depreciation provisioning and interest cost due to
TRCL	202	1,214	(83.4)	-37		its heavy capex.
UTCEM	26,821	23,240	15.4	14,344	87.0	SRCM fall in profits was a negative surprise.
Aggregate	59,324	49,183	20.6	21,429	176.8	



Fig 4 – Volume growth

(mn tonnes)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Comment
ACC	11.9	10.4	14.4	10.7	11.2	UTCEM remains a steady volume driver even if
ACEM	11.6	9.5	22.1	10.1	14.9	the base stayed high.
DALBHARA	8.6	8.8	(2.3)	6.7	28.4	SRCM's volume gains were muted and came as a
JKCE	5.7	5.1	12.0	4.7	21.0	negative surprise as it switched its focus between
JKLC	2.6	2.6	0.7	2.2	14.3	branding/premium category sales and volume push (as in H1FY25) in FY25.
SRCM	9.8	9.5	3.2	8.8	12.2	
STRCEM	1.5	1.4	8.6	1.1	43.6	<ul> <li>Volume gains by JKCE were 12%, aided by</li> </ul>
TRCL	5.2	5.4	(3.8)	4.4	19.0	capacity additions YoY in Central India region, while STRCEM remains a performer with ~9% volume growth in very challenging conditions.
UTCEM	36.6	33.4	9.7	28.3	29.4	
Aggregate	93.6	86.1	8.7	77.0	21.6	

Source: Company, BOBCAPS Research

Fig 5 - Realisation per tonne

(Rs/t)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Comment
ACC	4,780	4,908	(2.6)	4,652	2.8	<ul> <li>Aggregate realisation for our coverage fell by ~2%</li> </ul>
ACEM	4,898	5,032	(2.7)	4,806	1.9	YoY despite healthy demand, on equally strong
DALBHARA	4,757	4,895	(2.8)	4,748	0.2	supply pressure in eastern and southern India,
JKCE	5,865	5,773	1.6	5,765	1.7	<ul> <li>owing to year-end volume targets to compensate for the weak H1FY25 due to general elections and above-normal monsoons.</li> <li>Further, prices were also impacted by festive season (wanning demand) in the last month of the quarter.</li> </ul>
JKLC	6,766	6,459	4.7	6,109	10.8	
SRCM	5,325	5,350	(0.5)	4,830	10.3	
STRCEM	6,378	6,439	(0.9)	6,333	0.7	
TRCL	4,598	4,945	(7.0)	4,523	1.7	
UTCEM	4,719	5,193	(9.1)	4,984	(5.3)	
Aggregate	4,809	4,899	(1.9)	4,675	2.9	

Source: Company, BOBCAPS Research

Fig 6 - Operating cost per tonne

(Rs/t)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Comment
ACC	4,309	4,386	(1.7)	4,474	(3.7)	Operating cost savings helped guard against a
ACEM	4,003	4,192	(4.5)	4,399	(9.0)	sharper fall in EBITDA margin. Operating cost per
DALBHARA	3,835	4,151	(7.6)	3,985	(3.8)	tonne for our coverage companies fell by 2%, driven by energy and logistics cost savings.
JKCE	4,573	4,697	(2.6)	4,726	(3.2)	<ul> <li>However, cost savings have inched up QoQ for those companies using higher imported coal or pet-coke prices, indicating that the cost-saving</li> </ul>
JKLC	5,823	5,380	8.2	5,475	6.4	
SRCM	3,916	3,958	(1.1)	3,750	4.4	
STRCEM	5,153	5,201	(0.9)	5,759	(10.5)	avenues are waning steadily.  Companies shifting aggressively to green energy
TRCL	3,981	4,174	(4.6)	3,884	2.5	sources will continue having additional levers of
UTCEM	4,514	4,729	(4.6)	4,788	(5.7)	cost savings.
Aggregate	4,011	4,087	(1.9)	4,124	(2.7)	



Fig 7 - EBITDA per tonne

(Rs/t)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Comment
ACC	740	805	(8.1)	442	67.6	<ul> <li>Aggregate EBITDA/tonne improved by a slow 2%</li> </ul>
ACEM	895	840	6.6	407	119.9	pace, dragged down by companies with higher
DALBHARA	895	717	24.9	736	21.7	exposure to southern and eastern regions.
JKCE	1,292	1,075	20.1	1,040	24.3	<ul> <li>JKCE's outperformance was striking, since its presence in Central India is getting further consolidated.</li> <li>The improvement could have been higher, but for the heavy dent by companies like ACC and TRCL.</li> </ul>
JKLC	943	1,080	(12.7)	634	48.7	
SRCM	1,409	1,392	1.2	1,079	30.6	
STRCEM	1,225	1,238	(1.1)	574	113.5	
TRCL	598	753	(20.6)	617	(3.1)	
UTCEM	1,259	1,204	4.5	982	28.3	
Aggregate	926	910	1.7	651	42.2	


Source: Company, BOBCAPS Research

Logistics costs for our coverage inched by ~2% YoY as the lead distance increased by 10-20kms to chase higher volume.

SRCM, JKLC, JKCE and STRCEM's costs rose sharply by an average of 11%, while ACC/ACEM were the biggest beneficiaries in Q4 (average fall of 12% YoY).


Fuel costs for our coverage companies dropped 7%/3% YoY/QoQ, as energy prices continue to soften. However, the benefits will wane steadily on a lower base in the next few quarters, in our view.

Fig 8 - Logistics cost per tonne



Source: Company, BOBCAPS Research

Fig 9 - Power & fuel cost per tonne






Average margin gained 130bps YoY to 20.3% in Q4FY25. The improvement was driven by solely by cost savings that offset pricing weakness.

UTCEM, STRCEM, JKCE and ACEM continued to have above-average gains.

JKLC, TRCL and ACC's margins stayed below par.

Margins improved as cost savings offered healthy respite in offsetting the dent in realisations in Q4FY25.

Fig 10 - EBITDA margin



Source: Company, BOBCAPS Research

Fig 11 - Realisations vs margins






Fig 12 – Ongoing expansion projects

Company	Projects
ACC	Cement
7.00	Jodhpur Penna IU - 2 mnt by Q3FY26
	Sankrail - 2.4 mnt by Q1FY26
	Sindri - 1.6 mnt by Q1FY26
	Salai Banwa - 2.4 mnt by Q2FY26
	Bathinda - 1.2 mnt by Q3FY26
	Marwar - 2.4 mnt by Q3FY26
	Warishaliganj - 2.4 mnt by Q4FY26
	Dahej Line 2 - 1.2 mnt by Q3FY26
	Kalamboli - 1.0 mnt by Q3FY26
ACEM	Krishnapatnam Penna - 2.0 mnt by Q2FY26
	Clinker
	Bhatapara Line 3 - 4 mnt by Q1FY26
	Maratha Line 2 - 4 mnt by Q3FY26
	Jodhpur Penna IU - 3 mnt by Q3FY26
	ACEM has planned growth capex of Rs 60bn and efficiency capex of Rs 25-30bn totalling to Rs 90bn for FY26
	Cement
	Belgaum - 3mnt by FY27
	Clinkan
	Clinker
	Umranghsu - 3.6 mnt by FY26
	Belgaum - 3.6mnt by FY27
DALBHARA	Pune - 3mnt by FY27
	Captive Energy
	Lanka, Assam - 2.2mw solar power plant
	Group Captive - 13mw RE capacity
	Total capex for FY25 was ~Rs 24bn and for FY26 management has guided Rs 35bn.
Heidelberg Cement	-
	Cement
	3 mnt Cement Capacity at Panna, Hamirpur & Prayagraj (1 MTPA at each location)
	3 mnt Split Grinding Unit at Bihar
	Clinker
JKCE	3.3 mnt Grey Clinker Capacity at Panna
	Cabadula Commissionina Design (Institut
	Schedule Commissioning - Dec'25/Jan'26
	Capex guidance for FY26 is Rs 18-20bn. Exapnsion plans post FY26 are under evaluation for Jaisalmer, Karnataka, Orissa and additional Pnna
	line.
	Cement
	Surat Grinding Unit (Phase 1) - 0.7 mnt by Jun' 25
	Surat Grinding Unit (Phase 2) - 0.65mnt by Sept'25
	Durg, Chattisgarh -4.6 mnt (Q3FY27)
	Prayagraj (FY27), Madhubani (FY27), Patratu (FY28) - 3.4 mnt.
JKLC	
	Clinker
	Durg, Chattisgarh -2.3 mnt (Q3FY27)
	0
	Capex guidance for FY26 is Rs 13bn (JKLC - Rs 11bn including Durg, Northeast - Rs 1.5bn, UCWL - Rs 0.5bn)
	Conveyor belt project capex is planned at Rs 0.7-0.8bn and scheduled to commission by Mar'26



	Cement
	Jaitaran, Rajasthan - 3mnt by Q1FY26
	Kodla, Karnataka - 3mnt by Q2FY26
SRCM	Clinker
	7.3mn tonnes of clinker capacity will be added, bringing the total clinker capacity to 44mn tonnes by the end of FY26
	7.5mm torries of clinical capacity will be added, bringing the total clinical capacity to 44mm torries by the crit of 1.125
	Management has guided Rs 30bn capex for FY26.
	Cement
	Silchar GU, Assam - 2mnt (Q4FY26)
STRCEM	Jorhat GU, Assam - 2mnt (Q4FY27)
	Capex spent for FY25 was at Rs 5.62bn; management has earmarked a capex of Rs 8.23bn for FY26 and Rs 6bn for FY27.
	Management has reiterated their target to achieve cement capacity of 30MTPA by Mar'26 with the commissioning of 2nd line in Kolimigundla along
	with de-bottlenecking of existing facilities / adding grinding capacities in existing locations with minimal capex.
	Construction of railway siding in Kolimigundla is completed and commissioning is expected by Q1FY26.
TRCL	
	By Jul'25, 10mw of WHRS at Ramasamy Raja Nagar and another 15mw of WHRS in Kolimigundla are anticipated to be put into service, together
	with Kiln Line-2.
	The capex guidance for FY26 is Rs 12bn.
	Cement
	Patratu, Jharkhand - 2.5 mnt by FY26
	Maihar, Madhya Pradesh (Phase 2) - 1.8mnt by F26
	Shahjahanpur, Uttar Pradesh - 1.8 mnt by FY26
	Nathdwara, Rajasthan - 1.2 mnt by FY26
	Dhule, Maharashtra (Phase 2) - 0.6 mnt by FY26
	Visakhapatnam, Andhra Pradesh - 3.3 mnt by FY26
	Parli, Maharashtra- 1.2 mnt by FY26
	Panvel, Maharashtra - 1.0 mnt by FY26
UTCEM	
	Aligarh, Uttar Pradesh - 2.7 mnt by FY27
	Bihar - 3.3 mnt by FY27
	West Bengal - 3.3 mnt by FY27
	APCW, Andhra Pradesh - 2.7 mnt by FY27
	Andhra Pradesh - 2.7 mnt by FY2
	Gujarat - 1.2 mnt by FY27
	Kamataka - 1.2 mnt by FY27
	Assam - 1.2 mnt by FY27
	Tamil Nadu - 1.8 mnt by FY27
Sanghi Industries	•

 $Source: Company, BOBCAPS \ Research \ | \ GU: Grinding \ Unit; \ IU: \ Integrated \ Unit; \ WHRS: \ Waste \ heat \ recovery \ systems, \ mnt: \ million \ tonnes$ 



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

# **Disclaimer**

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009

Logo:



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### **Analyst certification**

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.



### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

## Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

## Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.